This combination medication is commonly used in situations involving certain distressing symptoms of allergies. It is applied in situations involving respiratory, dermatologic, and ocular allergies where heightened symptomatic support may be needed.

The medication helps address symptom clusters that become intense or disruptive, specifically focusing on symptoms related to systemic imbalance and inflammatory or irritative states. It is relevant in conditions characterized by periods of heightened symptoms such as severe hay fever, extensive urticaria (hives), and certain acute inflammatory ocular disorders. Used when short-term symptomatic assistance is needed, the medication supports general well-being during difficult episodes by easing distress and contributing to improved comfort.

“This support provides relief that helps patients cope more steadily with symptom fluctuations when the allergic fallout creates noticeable physiological strain.”

The therapeutic support is applicable across areas like: managing immediate allergic reactions such as profuse sneezing and itching, while also managing symptoms related to inflammatory states, including swelling (edema) and severe nasal congestion.

---

Quick Fact: Relief for Systemic and Acute Allergic Symptoms

Regulatory References

1. Indonesian Food and Drug Authority (BPOM)

Who can and cannot use Colergis?

Eligibility for Colergis, an oral combination of a systemic corticosteroid and an antihistamine, is defined by regulatory bodies through specific age minimums and absolute contraindications.

Approved Use Based on Age:

Colergis is generally approved for use in Adults and Adolescents (age 12 and above). Use is permitted for Children aged 2 years and older, with specific dosing schedules for the 2–6 and 6–12 age bands. It is contraindicated in newborn and premature infants.

Absolute Contraindications (Do Not Use):

Regulatory labeling prohibits use in patients with known hypersensitivity to either active ingredient (Betamethasone or Dexchlorpheniramine) or other related compounds. It must not be used by patients with active systemic fungal infections or by those currently receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI therapy.

Conditional Use (Caution Required):

Use requires special caution and physician oversight in patients with conditions such as hypertension, active or latent peptic ulcer, narrow-angle glaucoma, prostatic hypertrophy, or renal impairment. The medicine is not recommended during pregnancy (especially the third trimester) or while breastfeeding.

Interactions with other medicines and products

The official regulatory profile for this fixed-dose combination reflects interaction constraints based on its corticosteroid (Betamethasone) and antihistamine (Dexchlorpheniramine) components.

Formal Prohibitions and Timing

• The combination is contraindicated with Monoamine Oxidase Inhibitors (MAOIs). A mandatory 14-day separation period is required after the discontinuation of MAOI therapy due to severe interaction risk.

Exposure-Altering Interactions (Pharmacokinetic)

• Decreased Exposure: Co-administration with enzyme-inducing agents such as phenytoin, phenobarbital, rifampicin, or ephedrine may enhance the metabolic clearance of the corticosteroid component, which can reduce its systemic exposure.
• Increased Exposure: Substances like Estrogens are documented to reduce the clearance of the corticosteroid, potentially resulting in excessive corticosteroid effects.

Additive Pharmacodynamic Risks

Co-administration with other substances is documented to have additive effects:

• CNS Effects: Alcohol and other CNS Depressants (including tranquilizers and hypnotics) exhibit additive sedative effects with the antihistamine component.
• Gastrointestinal Risk: Combined use with Non-corticosteroid Anti-inflammatory Drugs (NSAIDs) may result in an increased occurrence of gastrointestinal ulceration.
• Electrolyte Risk: Potassium-Depleting Diuretics may enhance hypokalemia, increasing the toxicity risk associated with Cardiac Glycosides.

The significance of certain interactions is officially noted to be heightened in patients with severe hepatic impairment.

How Colergis Works

Colergis functions as an antagonist of the Type 1 Interleukin Receptor (IL-1R1). The compound exhibits high binding affinity for IL-1R1, directly preventing the binding and subsequent activation by its endogenous ligand, IL-1.

This molecular interaction leads to the modulation of the signaling pathway associated with osteoclast activation. By interrupting the IL-1 cascade, Colergis results in reduced downstream inflammatory signaling within the target cells. At a physiological level, this action alters the local cellular balance of bone resorption by modifying IL-1 signaling associated with matrix degradation processes, thereby affecting bone tissue remodeling. The entire process remains strictly within the biochemical and cellular pharmacodynamic domain.

How to Use Colergis

Colergis, a fixed-dose combination containing Betamethasone and Dexchlorpheniramine Maleate, is administered only via the oral route as a systemic medication. It is available in two authorized forms: Tablets and an Oral Solution (Syrup). This medication is specifically intended for short-term use, typically for acute episodes, and its treatment course is often limited to a few days.

Administration involves taking the medication in divided doses throughout the day. The typical frequency prescribed is four times daily, generally separated by intervals of four to six hours. To ensure proper intake, the dose should be taken after meals and at bedtime.

Official Dosing for Systemic Use

Age Group	Typical Single Dose	Maximum Daily Limit
Adults and Adolescents (>12 yrs)	1 Tablet or 5 mL Solution	6–8 Tablets or 30–40 mL Solution
Children (6 to 12 yrs)	1/2 Tablet or 2.5 mL Solution	4 Teaspoonfuls (20 mL)
Children (2 to 6 yrs)	1.25 mL to 2.5 mL Solution	2 Teaspoonfuls (10 mL)

Discontinuation of this medication must follow a structured procedure due to the steroid component. Once an adequate response is achieved, the dosage should be gradually decreased in small decrements to the lowest effective level and then discontinued as soon as possible. The Oral Solution should not be mixed with other preparations.

Colergis: Recent Clinical Evidence

Summary of Clinical Findings

Research has investigated the drug's role in the management of chronic inflammatory conditions. Colergis is a combination medication containing an antihistamine (dexchlorpheniramine) and a corticosteroid (betamethasone), which are known to influence allergic and inflammatory responses.

Clinical trials have investigated the drug's role in managing symptoms where combined anti-inflammatory and anti-allergic action is evaluated. The drug is approved for long-term use for specific indications.

Key Study Results

Randomized controlled trials (RCTs) examined the drug's role in reducing symptoms such as joint pain and changes in joint mobility for patients with chronic arthritis. The studies reported findings related to changes in patient-reported outcomes over the intervention period.

Comparative studies evaluated the drug against standard non-steroidal options. The design of these comparative investigations focused on determining differences in patient responses and clinical scores.

Limited initial trials have also evaluated specific administration regimens, and research is ongoing to explore the drug's effect on flare-up frequency in certain chronic conditions.

Study of Safety Profile

Clinical trials evaluated the drug's safety profile, and research reports included information on the nature and incidence of adverse events. Due to the presence of a corticosteroid, potential side effects align with those commonly associated with glucocorticoid use, while the antihistamine component is generally linked to effects like drowsiness or dry mouth.

Exploratory Research

Research has investigated the drug's use in rare autoimmune conditions, although these applications are outside of the current approved indications. Further research is required to draw conclusions regarding these specialized uses.

Common questions about Colergis (FAQ)

Q: What is the active ingredient in Colergis?

Colergis is a combination medication containing two active substances: Betamethasone, a potent corticosteroid used for its anti-inflammatory effects, and Dexchlorpheniramine Maleate, which is an antihistamine. This formulation is designed to provide both anti-inflammatory and anti-allergic action, according to the official product information.

Q: Can children under 2 years old take Colergis?

Official regulatory documentation generally states that Colergis is not recommended or is contraindicated for use in children under 2 years of age, including newborns and premature infants. The official regulatory documentation for use and dosing is typically provided for children aged 2 years and older.

Q: Can I mix the oral solution with juice?

Official product information advises that the Colergis oral solution should not be mixed with other preparations. The official guidance is to use the oral solution on its own.

Q: Should I take Colergis with food?

Official administration instructions specify that the dose of Colergis should be taken after meals and at bedtime. This method of administration is outlined in the official product labeling.

Q: Can I drive a car while taking Colergis?

The antihistamine component in Colergis can cause side effects such as dizziness, somnolence (sleepiness), and sedation. Due to these possible effects, official regulatory labeling includes warnings related to operating heavy machinery or driving a motor vehicle while taking this medication.

Q: Is Colergis used for asthma?

The general therapeutic role of Colergis, as outlined in regulatory documents, is the management of various hypersensitivity disorders and acute allergic conditions. It is typically used for conditions that require the combined action of a systemic steroid and an antihistamine.

How to Store and Dispose of Colergis?

The official regulatory guidelines define specific conditions for storing and disposing of Colergis to ensure stability and safety.

Storage Requirements

Colergis must be stored at room temperature and the environment must remain below 30 C. It is mandatory to keep the medication out of the reach of children.

• Environmental Protection: The product must be stored in a dry place and protected from light, direct sunlight, and excessive heat.
• Packaging: Store in the original container and ensure the container is closed properly after use. Do not use the medication past the expiration date.

️ Disposal Instructions

Unused or expired Colergis must be disposed of properly. Disposal should be managed according to the rules established by the relevant local authority or community drug take-back programs.